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The Editorial on the Research Topic
5-HT2A/2B/2C Receptors, Memory, and Neuropsychiatric Disorders
It is very well known that memory formation and forgetting represent important cognitive
functions modulated by several neurotransmitters, including serotonin (5-hydroxytryptamine, 5-
HT) (e.g., Fioravanti and Di Cesare, 1992; Wagner and Davachi, 2001; Wixted, 2004; Mansuy,
2005; Hardt et al., 2013; Hupbach; Callaghan et al., 2014; Li et al., 2015; Meneses), and memory
dysfunction is present in several neuropsychiatric disorders (Meyer-Lindenberg et al., 2012; Millan
et al., 2012, 2014). How does the brain become dysfunctional? Such a question has intrigued
neuroscientists for many years. Over recent decades, neuroscience research has shed light on this
complex issue and growing evidence is providing important insights. For instance, several lines of
evidence demonstrate that dysfunctions in memory processes occur in several neuropsychiatric
disorders, including Alzheimer’s disease (AD), characterized by memory deficits and dementia;
however, dysfunctional memory is observed in other age-related neurodegenerative disorders, such
as schizophrenia, post-traumatic stress disorder, stroke, etc. (Millan et al., 2014; Hashimoto, 2015).
So far, no effective treatment for dysfunctional memory exists (e.g., Millan et al., 2012, 2014; Sun
et al., 2015); this area is hampered by the absence of neural markers associated to memory. Hence,
progress in the fields relating to memory, amnesia, forgetting (e.g., Tellez et al., 2012) and AD
(e.g., McConathy and Sheline, 2015; Muenchhoff et al., 2015; Scarr et al., 2015) as well as mild
cognitive impairment (Eshkoor et al., 2015) would be facilitated considerably by identification
of suitable neural markers. Serotonin is involved in several physiological and pathophysiological
processes in mammals and in the treatment of psychiatric disorders (Meneses). It is very well
known that 5-HT receptor heterogeneity allows for greater advances, and 5-HT 2A/2B/2C receptors
are emerging as important tools for preclinical and clinical investigation. This special issue provides
a deep overview of important advances on cerebral modifications associated with neuropsychiatric
alterations, including dysfunctional memory. In particular, some papers analyse the role of
serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
(Sumiyoshi et al.), while others are focused on the missing link of the central serotonin-2A 5-
HT2A receptor dysfunction in depression and epilepsy (Guiard and Di Giovanni) and on the
activity-regulated cytoskeleton-associated protein’s putative role in regulating dendritic plasticity,
cognitive processes, and mood in animal models of depression is presented (Li et al.). Moreover,
a critical evaluation of serotonin mediation of early memory formation via 5-HT2B receptor-
induced glycogenolysis in the day-old chick is provided (Gibbs and Hertz). An important subject is
the neuronal localization of the 5-HT2 receptor family in the amygdaloid complex and emotion
memories (Bombardi). Modeling dysfunctional memory, mitochondrial energy metabolism in
different regions of the brain and potential treatments is illustrated (Singh and Kumar). In short,
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the translational feature of this special issue may expand
our knowledge on brain dysfunctions and inspire further
investigation, thus leading to a better management of psychiatric
diseases.
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